

NCCN Clinical Practice Guidelines in Oncology
(NCCN Guidelines®)

Acute Myeloid Leukemia

Overall management of Acute Myeloid Leukemia is described in the full NCCN Guidelines® for Acute Myeloid Leukemia. Visit NCCN.org to view the complete library of NCCN Guidelines.

Reproduced with permission from the NCCN Guidelines for Acute Myeloid Leukemia V.1.2022. © 2022 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines® and illustrations herein may not be reproduced in any form for any purpose without the express written permission of NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. The NCCN Guidelines are a work in progress that may be refined as often as new significant data becomes available.

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Provided by Jazz Pharmaceuticals:

INDICATION

VYXEOS® (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.


IMPORTANT SAFETY INFORMATION

WARNING: DO NOT INTERCHANGE WITH OTHER DAUNORUBICIN AND/OR CYTARABINE-CONTAINING PRODUCTS
VYXEOS has different dosage recommendations than daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. Verify drug name and dose prior to preparation and administration to avoid dosing errors.

CONTRAINDICATIONS

VYXEOS is contraindicated in patients with a history of serious hypersensitivity reactions to cytarabine, daunorubicin, or any component of the formulation.

Please see additional [Important Safety Information](#) on page 10 and [full Prescribing Information](#), including BOXED Warning.



Note: All recommendations are category 2A unless otherwise indicated.
 Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

Visit NCCN.org to view the complete library of NCCN Guidelines. Provided by Jazz Pharmaceuticals:

Patients may receive up to 2 cycles of induction of dual-drug liposomal daunorubicin and cytarabine (VYXEOS®, daunorubicin and cytarabine). The second cycle of induction—if needed, and if there was no unacceptable toxicity after the first cycle—consists of cytarabine 100 mg/m² and daunorubicin 44 mg/m² on Days 1 and 3.


The Phase 3 study of VYXEOS included adults aged 60-75 years with newly-diagnosed t-AML and AML-MRC.

Please see [Important Safety Information](#) on page 10 and [full Prescribing Information](#), including BOXED Warning.

FOOTNOTES FOR TREATMENT INDUCTION ELIGIBLE (AGE <60 YEARS)

- ^a Patients with elevated blast counts are at risk for tumor lysis and organ dysfunction secondary to leukostasis. Measures to rapidly reduce the WBC count include apheresis, hydroxyurea, and/or a single dose of cytarabine (1–2 g). Prompt institution of definitive therapy is essential.
- ^b Poor performance status and a comorbid medical condition, in addition to age, are factors that influence ability to tolerate standard induction therapy.
- ^c Patients with CBF-AML may benefit from the addition of gemtuzumab ozogamicin. Consider screening with fluorescence in situ hybridization (FISH) to identify translocations/abnormalities associated with CBF-AML. Gemtuzumab ozogamicin is not beneficial in patients with adverse risk AML.
- ^d Borlenghi E, et al. *J Geriatr Oncol* 2021;12:550-556.
- ^e For CBF-AML leukemia with *FLT3* mutation, the panel prefers gemtuzumab ozogamicin.
- ^f Gemtuzumab ozogamicin may be beneficial in *NPM1*-mutated AML (Kapp-Schwoerer S, et al. *Blood* 2020;136:3041-3050).
- ^g See [Principles of Supportive Care for AML \(AML-E\)](#).
- ^h See [Monitoring During Therapy \(AML-F\)](#).
- ⁱ Consider referral to palliative care for consultation at the start of induction. LeBlanc TW, et al. *Curr Hematol Malig Rep* 2017;12:300-308 and LeBlanc TW, et al. *J Oncol Pract* 2017;13:589-590. See [NCCN Guidelines for Palliative Care](#).
- ^j See [General Considerations and Supportive Care for AML Patients Who Prefer Not to Receive Blood Transfusions \(AML-D\)](#).
- ^k Burnett AK, et al. *J Clin Oncol* 2011;29:369-377. Meta-analyses showing an advantage with gemtuzumab ozogamicin have included other dosing schedules; Hills RK, et al. *Lancet Oncol* 2014;15:986-996.
- ^l Patients who receive transplant shortly following gemtuzumab ozogamicin administration may be at risk for developing sinusoidal obstruction syndrome (SOS). Wadleigh M, et al. *Blood* 2003;102:1578-1582. If transplant is planned, note that prior studies have used a 60- to 90-day interval between the last administration of gemtuzumab ozogamicin and HCT.
- ^m Threshold for CD33 is not well-defined and may be $\geq 1\%$.
- ⁿ ECOG reported a significant increase in complete response rates and overall survival using daunorubicin 90 mg/m² x 3 days versus 45 mg/m² x 3 days in patients <60 years of age. Fernandez HF, et al. *N Engl J Med* 2009;361:1249-1259. If there is residual disease on days 12–14, the additional daunorubicin dose is 45 mg/m² x 3 days. Burnett AK, et al. *Blood* 2015;125:3878-3885.
- ^o For patients with impaired cardiac function, other cytarabine-based regimens alone or with other agents can be considered. See [Discussion](#).
- ^p An FDA-approved biosimilar is an appropriate substitute for filgrastim.
- ^q Burnett AK, et al. *J Clin Oncol* 2013;31:3360-3368.
- ^r This regimen is for *FLT3* mutation-positive AML (both ITD and TKD mutations). While midostaurin was not FDA approved for maintenance therapy, the study was designed for consolidation and maintenance midostaurin for a total of 12 months. Stone RM, et al. *N Engl J Med* 2017;377:454-464.
- ^s Outcomes with unfavorable-risk cytogenetics and *TP53*-mutated AML remain poor with conventional induction chemotherapy (Rücker FG, et al. *Blood* 2012;119:2114-2121). Consider clinical trials, azacitidine/venetoclax (DiNardo CD, et al. *N Engl J Med* 2020;383:617-629), or a 10-day course of decitabine (Welch JS, et al. *N Engl J Med* 2016;375:2023-2036).
- ^t There are limited data supporting the use of this regimen in patients aged <60 years. Lancet JE, et al. *J Clin Oncol* 2018;36:2684-2692.
- ^u The use of high-dose cytarabine for induction outside the setting of a clinical trial is still controversial. While the remission rates are the same for standard- and high-dose cytarabine, two studies have shown more rapid marrow blast clearance after one cycle of high-dose therapy. Kern W and Estey EH. *Cancer* 2006;107:116-124.
- ^v Weick JK, et al. *Blood* 1996;88:2841-2851.
- ^w Bishop JF, et al. *Blood* 1996;87:1710-1717.
- ^x Willemze R, et al. *J Clin Oncol* 2014;32:219-228.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



See footnotes on AML-4A

Note: All recommendations are category 2A unless otherwise indicated.
 Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

Version 1.2022. 12/02/21 © 2021 National Comprehensive Cancer Network® (NCCN®). All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

AML-4

Visit NCCN.org to view the complete library of NCCN Guidelines. Provided by Jazz Pharmaceuticals:

Patients may receive up to 2 cycles of consolidation of dual-drug liposomal daunorubicin and cytarabine (VYXEOS®, daunorubicin and cytarabine). Both cycles of consolidation consist of cytarabine 65 mg/m² and daunorubicin 29 mg/m² on Days 1 and 3.

The Phase 3 study of VYXEOS included adults aged 60-75 years with newly-diagnosed t-AML and AML-MRC.

Please see [Important Safety Information](#) on page 10 and [full Prescribing Information](#), including BOXED Warning.

FOOTNOTES FOR CONSOLIDATION THERAPY (AGE <60 YEARS)

- ^l Patients who receive transplant shortly following gemtuzumab ozogamicin administration may be at risk for developing SOS. Wadleigh M, et al. *Blood* 2003;102:1578-1582. If transplant is planned, note that prior studies have used a 60- to 90-day interval between the last administration of gemtuzumab ozogamicin and HCT.
- ^r This regimen is for *FLT3* mutation-positive AML (both ITD and TKD mutations). While midostaurin was not FDA approved for maintenance therapy, the study was designed for consolidation and maintenance midostaurin for a total of 12 months. Stone RM, et al. *N Engl J Med* 2017;377:454-464.
- ^z Begin alternate donor search (haploidentical, unrelated donor, or cord blood) if no appropriate matched sibling donor is available and the patient is a candidate for allogeneic HCT. For induction failure, alternative therapy to achieve remission is encouraged prior to HCT.
- ^{hh} *FLT3*-ITD mutation is a poor-risk feature in the setting of otherwise normal karyotype, and these patients should be considered for clinical trials where available.
- ⁱⁱ Mayer RJ, et al. *N Engl J Med* 1994;331:896-903; Jaramillo S, et al. *Blood Cancer J* 2017;7:e564.
- ^{jj} Alternate dosing of cytarabine for postremission therapy has been reported (see [Discussion](#)). Jaramillo S, et al. *Blood Cancer J* 2017;7:e564.
- ^{kk} Meta-analyses showing an advantage with gemtuzumab ozogamicin have included other dosing schedules. Hills RK, et al. *Lancet Oncol* 2014;15:986-996.
- ^{ll} This regimen may also be used in patients with KIT mutations because the outcomes are similar in patients without KIT mutations.
- ^{mmm} Patients may require at least one cycle of high-dose cytarabine consolidation while donor search is in progress to maintain remission. Patients may proceed directly to transplant following achievement of remission if a donor (sibling or alternative) is available.
- ⁿⁿ There is no evidence that HIDAC is superior to intermediate doses (1.5 g/m² daily x 5 days) of cytarabine in patients with intermediate-risk cytogenetics.
- ^{oo} Lancet JE, et al. *J Clin Oncol* 2018;36:2684-2692.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

Version 1.2022. 12/02/21 © 2021 National Comprehensive Cancer Network® (NCCN®). All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.


AML-4A

Visit NCCN.org to view the complete library of NCCN Guidelines. Provided by Jazz Pharmaceuticals:

Patients may receive up to 2 cycles of consolidation of dual-drug liposomal daunorubicin and cytarabine (VYXEOS®, daunorubicin and cytarabine). Both cycles of consolidation consist of cytarabine 65 mg/m² and daunorubicin 29 mg/m² on Days 1 and 3.

The Phase 3 study of VYXEOS included adults aged 60-75 years with newly-diagnosed t-AML and AML-MRC.

Please see [Important Safety Information](#) on page 10 and [full Prescribing Information](#), including BOXED Warning.



See footnotes on AML-5A


Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

FOOTNOTES FOR TREATMENT INDUCTION (AGE ≥60 YEARS)

- ^a Patients with elevated blast counts are at risk for tumor lysis and organ dysfunction secondary to leukostasis. Measures to rapidly reduce the WBC count include apheresis, hydroxyurea, and/or a single dose of cytarabine (1–2 g). Prompt institution of definitive therapy is essential.
- ^g See [Principles of Supportive Care for AML \(AML-E\)](#).
- ⁱ Consider referral to palliative care for consultation at the start of induction. LeBlanc TW, et al. *Curr Hematol Malig Rep* 2017;12:300-308 and LeBlanc TW, et al. *J Oncol Pract* 2017;13:589-590. See [NCCN Guidelines for Palliative Care](#).
- ^j See [General Considerations and Supportive Care for Patients Who Prefer Not to Receive Blood Transfusions \(AML-D\)](#).
- ^l Patients who receive transplant shortly following gemtuzumab ozogamicin administration may be at risk for developing SOS. Wadleigh M, et al. *Blood* 2003;102:1578-1582. If transplant is planned, note that prior studies have used a 60- to 90-day interval between the last administration of gemtuzumab ozogamicin and HCT.
- ^m Threshold for CD33 is not well-defined and may be ≥1%.
- ^r This regimen is for *FLT3* mutation-positive AML (both ITD and TKD mutations). While midostaurin was not FDA approved for maintenance therapy, the study was designed for consolidation and maintenance midostaurin for a total of 12 months. Stone RM, et al. *N Engl J Med* 2017;377:454-464.
- ^{kk} Meta-analyses showing an advantage with gemtuzumab ozogamicin have included other dosing schedules. Hills RK, et al. *Lancet Oncol* 2014;15:986-996.
- ^{oo} *Lancet JE*, et al. *J Clin Oncol* 2018;36:2684-2692.
- ^{pp} There is a web-based scoring tool available to evaluate the probability of complete response and early death after standard induction therapy in elderly patients with AML: <http://www.aml-score.org/>. Krug U, et al. *Lancet* 2010;376:2000-2008. A web-based tool to predict CR and early death can be found at: <https://trmcalculator.fredhutch.org> and Walter RB, et al. *J Clin Oncol* 2011;29:4417-4423. Factors in decisions about fitness for induction chemotherapy include age, performance status, functional status, and comorbid conditions. See [NCCN Guidelines for Older Adult Oncology](#).
- ^{qq} Patients with *TP53* mutations are a group with poor prognosis, and should be considered for enrollment in clinical trials.
- ^{rr} Castaigne S, et al. *Lancet* 2012;379:1508-1516.
- ^{ss} For patients who exceed anthracycline dose or have cardiac issues but are still able to receive aggressive therapy, alternative non-anthracycline-containing regimens may be considered (eg, FLAG, clofarabine-based regimens [category 3]).
- ^{tt} The complete response rates and 2-year overall survival in patients between 60 and 65 years of age treated with daunorubicin 90 mg/m² is also comparable to the outcome for idarubicin 12 mg/m²; the higher-dose daunorubicin did not benefit patients >65 years of age (Löwenberg B, et al. *N Engl J Med* 2009;361:1235-1248).
- ^{uu} The RATIFY trial studied patients aged 18–60 y. An extrapolation of the data suggests that older patients who are fit to receive 7+3 should be offered midostaurin since it seems to provide a survival benefit without undue toxicity. Schlenk RF, et al. *Blood* 2019;133:840-851.
- ^{vv} This regimen may be continued for patients who demonstrate clinical improvement (CR/CRi), with consideration of subsequent transplant, where appropriate. DiNardo CD, et al. *Lancet Oncol* 2018;19:216-228; Wei A, et al. *Blood* 2017;130:890; Wei A, et al. *Haematologica* 2017; Abstract S473; DiNardo CD, *Blood* 2019;133:7-17; DiNardo CD, et al. *N Engl J Med* 2020;383:617-629.
- ^{ww} Patients who have progressed to AML from MDS after significant exposure to hypomethylating agents (HMAs) (ie, azacitidine, decitabine) may be less likely to derive benefit from continued treatment with HMAs compared to patients who are HMA-naïve. Alternative treatment strategies should be considered.
- ^{xx} Wei AH, et al. *J Clin Oncol* 2019;37:1277-1284.
- ^{yy} Regimens that include gemtuzumab ozogamicin have limited benefit in patients with poor-risk disease.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**AGE ≥60 y
POST-INDUCTION THERAPY**



See footnotes on [AML-8A](#)

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

FOOTNOTES FOR POST-INDUCTION THERAPY (AGE ≥60 YEARS)

- ^r This regimen is for *FLT3* mutation-positive AML (both ITD and TKD mutations). While midostaurin was not FDA approved for maintenance therapy, the study was designed for consolidation and maintenance midostaurin for a total of 12 months. Stone RM, et al. *N Engl J Med* 2017;377:454-464.
- ^{ee} For regimens using high cumulative doses of cardiotoxic agents, consider reassessing cardiac function prior to each anthracycline/mitoxantrone-containing course. Karanes C, et al. *Leuk Res* 1999;23:787-794.
- ^{kk} Meta-analyses showing an advantage with gemtuzumab ozogamicin have included other dosing schedules. Hills RK, et al. *Lancet Oncol* 2014;15:986-996.
- ^{oo} *Lancet* JE, et al. *J Clin Oncol* 2018;36:2684-2692.
- ^{kkk} HLA typing should be used for patients considered to be strong candidates for allogeneic transplantation.
- ^{lll} Patients who are deemed as candidates for HCT and who have an available donor should be transplanted in first remission.
- ^{mmm} Alternate administration of intermediate-dose cytarabine may also be used. Sperr WG, et al. *Clin Cancer Res* 2004;10:3965-3971. The RATIFY trial studied patients aged 18–60 y. An extrapolation of the data suggests that older patients who are fit to receive 7+3 should be offered midostaurin since it seems to provide a survival benefit without undue toxicity. Schlenk RF, et al. *Blood* 2019;133:840-851.
- ⁿⁿⁿ This is not intended to replace consolidation chemotherapy. In addition, fit patients with intermediate- and/or adverse-risk cytogenetics may benefit from HCT in first CR, and there are no data to suggest that maintenance therapy with oral azacitidine can replace HCT. The panel also notes that the trial did not include younger patients or those with CBF-AML; it was restricted to patients ≥55 years of age with intermediate or adverse cytogenetics who were not felt to be candidates for HCT. Most patients received at least 1 cycle of consolidation prior to starting oral azacitidine. Wei AH, et al. *N Engl J Med* 2020;383:2526-2537.
- ^{ooo} Azacitidine: Huls G, et al. *Blood* 2019;133:1457-1464; Decitabine: Boumber Y, et al. *Leukemia* 2012;26:2428–3241.

**Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**

Version 1.2022, 12/02/21 © 2021 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

AML-8A

Visit NCCN.org to view the complete library of NCCN Guidelines. Provided by Jazz Pharmaceuticals:

Patients may receive up to 2 cycles of consolidation of dual-drug liposomal daunorubicin and cytarabine (VYXEOS®, daunorubicin and cytarabine). Both cycles of consolidation consist of cytarabine 65 mg/m² and daunorubicin 29 mg/m² on Days 1 and 3.

The Phase 3 study of VYXEOS included adults aged 60-75 years with newly-diagnosed t-AML and AML-MRC.

Please see [Important Safety Information](#) on page 10 and [full Prescribing Information](#), including BOXED Warning.

Provided by Jazz Pharmaceuticals:

VYXEOS® (daunorubicin and cytarabine) IMPORTANT SAFETY INFORMATION

WARNING: DO NOT INTERCHANGE WITH OTHER DAUNORUBICIN AND/OR CYTARABINE-CONTAINING PRODUCTS

VYXEOS has different dosage recommendations than daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. Verify drug name and dose prior to preparation and administration to avoid dosing errors.

Contraindications

VYXEOS is contraindicated in patients with a history of serious hypersensitivity reactions to cytarabine, daunorubicin, or any component of the formulation.

Warnings and Precautions

Hemorrhage

Serious or fatal hemorrhage events, including fatal CNS hemorrhages, associated with prolonged thrombocytopenia, have occurred with VYXEOS (daunorubicin and cytarabine). The overall incidence (grade 1-5) of hemorrhagic events was 74% in the VYXEOS arm and 56% in the control arm. The most frequently reported hemorrhagic event was epistaxis (36% in VYXEOS arm and 18% in control arm). Grade 3 or greater events occurred in 12% of VYXEOS-treated patients and in 8% of patients in the control arm. Fatal treatment-emergent CNS hemorrhage not in the setting of progressive disease occurred in 2% of patients in the VYXEOS arm and in 0.7% of patients in the control arm. Monitor blood counts regularly and administer platelet transfusion support as required.

Cardiotoxicity

VYXEOS contains daunorubicin, which has a known risk of cardiotoxicity. This risk may be increased in patients with prior anthracycline therapy, preexisting cardiac disease, previous radiotherapy to the mediastinum, or concomitant use of cardiotoxic drugs. Assess cardiac function prior to VYXEOS treatment and repeat prior to consolidation and as clinically required. Discontinue VYXEOS in patients with impaired cardiac function unless the benefit of initiating or continuing treatment outweighs the risk. VYXEOS is not recommended in patients with cardiac function that is less than normal.

Total cumulative doses of non-liposomal daunorubicin greater than 550 mg/m² have been associated with an increased incidence of drug-induced congestive heart failure. The tolerable limit appears lower (400 mg/m²) in patients who received radiation therapy to the mediastinum. Calculate the lifetime cumulative anthracycline exposure prior to each cycle of VYXEOS. VYXEOS is not recommended in patients whose lifetime anthracycline exposure has reached the maximum cumulative limit.

Hypersensitivity Reactions

Serious or fatal hypersensitivity reactions, including anaphylactic reactions, have been reported with daunorubicin and cytarabine. Monitor patients for hypersensitivity reactions. If a mild or moderate hypersensitivity reaction occurs, interrupt or slow the rate of infusion with VYXEOS and manage symptoms. If a severe or life-threatening hypersensitivity reaction occurs, discontinue VYXEOS permanently, treat the symptoms, and monitor until symptoms resolve.

Copper Overload

VYXEOS contains copper. Consult with a hepatologist and nephrologist with expertise in managing acute copper toxicity in

patients with Wilson's disease treated with VYXEOS. Monitor total serum copper, serum non-ceruloplasmin-bound copper, 24-hour urine copper levels, and serial neuropsychological examinations during VYXEOS treatment in patients with Wilson's disease or other copper-related metabolic disorders. Use only if the benefits outweigh the risks. Discontinue in patients with signs or symptoms of acute copper toxicity.

Tissue Necrosis

Daunorubicin has been associated with severe local tissue necrosis at the site of drug extravasation. Administer VYXEOS by the intravenous route only. Confirm patency of intravenous access before administration. Do not administer by intramuscular or subcutaneous route.

Embryo-Fetal Toxicity

VYXEOS can cause embryo-fetal harm when administered to a pregnant woman. Patients should avoid becoming pregnant while taking VYXEOS. If VYXEOS is used during pregnancy or if the patient becomes pregnant while taking VYXEOS, apprise the patient of the potential risk to a fetus. Advise females and males of reproductive potential to use effective contraception during treatment and for 6 months following the last dose of VYXEOS.

MOST COMMON ADVERSE REACTIONS

The most common adverse reactions (incidence ≥25%) were hemorrhagic events (74%), febrile neutropenia (70%), rash (56%), edema (55%), nausea (49%), mucositis (48%), diarrhea (48%), constipation (42%), musculoskeletal pain (43%), fatigue (39%), abdominal pain (36%), dyspnea (36%), headache (35%), cough (35%), decreased appetite (33%), arrhythmia (31%), pneumonia (31%), bacteremia (29%), chills (27%), sleep disorders (26%), and vomiting (25%).

The National Comprehensive Cancer Network® (NCCN®) appreciates that supporting companies recognize NCCN's need for autonomy in the development of the content of NCCN resources. All NCCN Guidelines are produced completely independently. NCCN Guidelines are not intended to promote any specific therapeutic modality. The distribution of this flashcard is supported by Jazz Pharmaceuticals, Inc. VYXEOS is a registered trademark of Jazz Pharmaceuticals plc or its subsidiaries.

Please see [full Prescribing Information](#), including **BOXED Warning**.

VYX-2000257 Rev0622
FC-JAZ-0171-0322